GLUCOCORTICOIDS IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: POSITIVE AND NEGATIVE ASPECTS
Glucocorticoids (GCs) are first-line drugs to treat systemic lupus erythematosus (SLE) of both high and moderate activities. These are the only agents that are able to provide so prompt anti-inflammatory and immunosuppressant effects in rheumatic diseases. Along with antimalarials and immunosuppress...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-11-01
|
| Series: | Klinicist |
| Subjects: | |
| Online Access: | https://klinitsist.abvpress.ru/Klin/article/view/150 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Glucocorticoids (GCs) are first-line drugs to treat systemic lupus erythematosus (SLE) of both high and moderate activities. These are the only agents that are able to provide so prompt anti-inflammatory and immunosuppressant effects in rheumatic diseases. Along with antimalarials and immunosuppressants, GCs are used in the standard classical treatment regimen for SLE; however, despite the high efficacy of these drugs, their related immediate or delayed adverse reactions are one of the major problems in the management of a patient with SLE. Occasionally, they may be severer than the indication itself for their use and may be even fatal. The paper describes the adverse reactions observed in a female patient with SLE during long-term use of a high maintenance GC dose. |
|---|---|
| ISSN: | 1818-8338 |